लोड हो रहा है...
NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
BACKGROUND: Oxaliplatin in combination with either 5-fluorouracil or capecitabine is commonly used as first line therapy for small bowel adenocarcinoma. The addition of irinotecan improves survival in other gastrointestinal tumors but at the cost of hematologic toxicity. We performed a phase II, coo...
में बचाया:
| में प्रकाशित: | Cancer |
|---|---|
| मुख्य लेखकों: | , , , , , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
2017
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5589489/ https://ncbi.nlm.nih.gov/pubmed/28493308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30766 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|